Podcast: Download (Duration: 9:36 — 11.4MB) | Embed
Subscribe: Google Podcasts | Spotify | Stitcher | Email | TuneIn | RSS | More
SmallCapVoice.com Inc. (“SCV”) announces the availability of a new audio interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss the positive FDA feedback on BriaCell’s pivotal study for lead clinical candidate Bria-IMT™ in combination with a checkpoint inhibitor could greatly accelerate the path to commercialization. Successful completion of the pivotal study could be followed by a Biologics License Application submission and commercialization. Pivotal study’s primary endpoint to be linked to survival improvement.
“We’re treating patients with very advanced breast cancer,” Dr. Williams says. “These are patients who have failed at least two prior therapies, but most of them have failed on the average of six to seven prior attempts of therapy for their metastatic breast cancer. These are very difficult-to-treat patients. Their life expectancy is very short; many of them would otherwise be going on hospice.”
